Accurately quantifying the proportion of glycosylated versus unoccupied sites on therapeutic proteins poses a significant analytical challenge, impacting critical quality attributes like stability and efficacy. Creative Biolabs' Glycosylation Site Occupancy Analysis Service directly addresses this need by providing precise macro-heterogeneity assessment. We employ a robust platform integrating optimized sample preparation with high-resolution mass spectrometry to measure site-specific occupancy. Our service delivers actionable data, enabling you to de-risk bioprocess development, ensure batch consistency, and strengthen your regulatory submission with quantitative, site-resolved evidence.
The HIV-1 envelope glycoprotein (Env) is densely glycosylated, shielding it from immune recognition. Many broadly neutralizing antibodies (bnAbs) target these glycans, making precise glycosylation analysis crucial for vaccine design. This study introduces a mass spectrometry-based method to quantitatively map site-specific glycan occupancy and type (high-mannose vs. complex) on Env trimers. This high-throughput approach provides essential insights for developing optimized immunogens.
Fig.1 Schematic overview of site-specific glycosylation analysis. 1
Creative Biolabs' Glycosylation Site Occupancy Analysis Service delivers an authoritative methodology for measuring glycosylation macro-heterogeneity, determining the exact proportion of occupied versus unoccupied sites on your therapeutic protein. We deliver more than identification—we generate a semi-quantitative map of structural maturity, differentiating unmodified positions, high-mannose/hybrid intermediates, and fully processed complex-type glycans. This granular detail is essential for designing vaccines that elicit robust neutralizing antibody responses and for engineering monoclonal antibodies with optimized pharmacokinetic profiles.
Our service offers complementary mass spectrometry strategies: rapid top-down intact protein analysis for a global occupancy overview, and precise bottom-up peptide-level analysis for detailed, site-specific quantification.
Beyond basic Glycosylation Site Occupancy Analysis, we offer a more advanced and specialized solution: Site-Specific Glycoform Analysis Services. This service enables precise characterization of the distinct glycan structures present at individual glycosylation sites, providing critical insights into how glycosylation heterogeneity influences protein function.
Required Starting Materials: To begin the service, please supply 100-500 µg of your purified glycoprotein (such as a monoclonal antibody or recombinant fusion protein), its amino acid sequence in FASTA format, and any relevant batch records or known stability issues.
Key Steps:
Final Deliverables: You will receive a complete analytical report containing high-resolution MS/MS spectra for every glycosylation site, quantified occupancy data (unoccupied versus occupied ratios), and intuitive data visualizations such as heatmaps and site-specific distribution charts.
We deliver actionable, multi-level glycosylation insights by uniquely integrating high-resolution intact protein analysis with site-specific micro-heterogeneity mapping. Our proprietary analytical framework simultaneously assesses both processing maturity and site occupancy, offering a critical advantage for developing and characterizing complex glyco-engineered biologics.
"Utilizing Creative Biolabs' precise glycosylation site occupancy analysis was instrumental for our biosimilar's regulatory submission. Their 18O labeling methodology delivered the conclusive, site-specific occupancy data directly requested by the regulatory review committee." Dr. A** S*****.
"This service was pivotal for our vaccine design. By dissecting high-mannose and complex-type glycans at individual sites, we could rigorously validate that our recombinant trimers structurally mimic the native viral surface." Prof. J*** R*****.
"The platform's advanced O-glycan profiling profoundly enhanced our fusion protein characterization. The optimized enrichment strategy identified densely clustered glycosylation sites that prior analyses had failed to detect." Dr. M** L*****.
To discuss how our site-specific glycosylation occupancy analysis can de-risk your therapeutic candidate and strengthen your CMC package, connect with our dedicated scientific experts. Request a project-specific consultation and a detailed proposal to advance your program today.
Reference
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.